Bbs Bioactive Bone Substitutes Stock Working Capital

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

In accordance with the company's disclosures, BBS Bioactive Bone Substitutes has a Working Capital of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Medical Devices industry. The working capital for all Finland stocks is 100.0% higher than that of the company.

The Macroaxis Fundamental Analysis modules help investors analyze BBS Bioactive Bone Substitutes's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BBS Bioactive using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BBS Bioactive Bone Substitutes based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

BBS Bioactive financial ratios help investors to determine whether BBS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BBS with respect to the benefits of owning BBS Bioactive security.